We count on a multidisciplinary consortium, where different stakeholders of this process are part of the study, from scientists to industry, and from healthcare providers (physicians and nurses) to patients. RESILIENCE is a patient-centred endeavour, where they take a key role in the development of the project, in close collaboration with healthcare providers (physicians and nurses), scientific societies and industry. Patients’ advocacy will be central throughout the span of the project
Over its relatively short existence, the CNIC has built an unrivalled infrastructure and a powerful, crossdisciplinary research base that embraces multiple disciplines and includes population and patient studies.
The CNIC Director is Dr.Valentín Fuster, a leading cardiovascular researcher and a world-renowned cardiologist. CNIC was awarded three times (2011, 2015, and 2020) with the “Severo Ochoa” distinction by the Spanish government in recognition of its leading international standing in cardiovascular research.
The CNIC boasts an agile management structure that promotes training and the exchange of ideas and expertise, as well as an unrivalled modern infrastructure of technical units and support services. Most importantly, the CNIC is funded through an innovative enterprise between the public sector and a private partner, the Pro-CNIC Foundation, which injects not only added financial security but also the wide- ranging business and management expertise of some of the most prominent Spanish businesses. The CNIC also benefits from the external support and advice of its Scientific Advisory Board, composed of leading international experts who provide guidance on strategy and recruitment and regularly evaluate the CNIC’s performance.
The CNIC building has a total floor space of 28,144 m2 and has capacity to house 383 scientists (60% women). CNIC is among the Spanish centers with highest training capacity and is organized to maximize collaboration between basic & clinical researchers and to encourage networking with hospitals. 32 research groups (7 led by clinicians) are distributed in 5 programs: (1) Novel mechanisms of atherosclerosis; 2) Myocardial homeostasis & cardiac injury; 3) CV regeneration; 4) Novel arrhythmogenic mechanisms; 5) CV risk factors & cognitive function.
CNIC is fitted with the latest generation of technological equipment. Most of the building is given over to laboratories equipped with the services and facilities necessary to perform high-quality biomedical research in an open environment that fosters maximum collaboration and communication between research groups. Core support facilities includes proteomics, genomics, animal facility, microscopy, cytometry, dynamic and quantitative microscopy, gene targeting and cell culture suites.
CNIC is equipped with unrivalled advanced imaging technology, with independent facilities devoted clinical imaging (digital 3T magnetic resonance imaging, hybrid PET/CT, ultrasound equipment), large animal imaging (digital 3T MRI, hybrid PET/CT, optical coherence tomography, ultrasound equipment), and small animal imaging (7T MRI, microPET/CT, high frequency ultrasound, optical and fluorescence imaging). CNIC was awarded by the Government as national Unique Scientific & Technical Infrastructure committed to transmission & preservation of knowledge, technology transfer & innovation (http://www.redib.net/)-
CNIC counts with 31 research groups and has participated in 34 projects funded under FP7 and 23 under H2020 (over 30 projects currently active). This participation includes 11 ERC Grants and 21 Marie Curie actions.
Concerning other results, tech transfer is important at the centre, the CNIC patent portfolio is currently composed by 18 patent families, 4 of them licensed. In 2018 CNIC presented 7 patent applications and entered into 2 new private-public collaborations with industry. In 2020, CNIC´s researchers published 289 documents (80% articles), and more than half of them were CNIC-led publications. A significant proportion were published in top journals (IF>10).
CNIC has a very strong presence in clinical research, currently coordinating >10 randomized clinical trials, including the H2020-funded SECURE trial, and the largest trial in Europe on the role of βblockers in myocardial infarction (REBOOT, where 8500 patients are being enrolled in several EU countries). Some of CNIC-led trials have changed clinical practice guidelines recommendations (such as FOCUS and METOCARD-CNIC trials).
CDue to its very active participation and leadership in clinical trials, CNIC launched in 2018 a Clinical Trials Coordination Unit (CTCU) which acts as academic CRO not only for trials led by CNIC but also for non-industry trials having aims aligned with the centre´s mission. Thanks to the CTCU, CNIC has been positioned as a leading European centre in the clinical trials arena.
The legal entity which will sign the contract with the EC is AMC. Amsterdam UMC provides hematologic consultations for a large number of hospitals in the Netherlands and is the referral center for tertiary care for these hospitals. The mission of the department of hematology is to cure more patients of cancer with less toxic and more targeted treatments.
Prof. Kersten (dept. of hematology AMC) and dr. Chamuleau (dept. Of hematology VUMC) are cochair and secretary of the board of the HOVON lymphoma group and prof. Kersten is chair of the HOVON/LLPC phase I/II consortium. Prof. Kersten is also involved in the BETER consortium, aiming at improving care for Hodgkin and NHL survivors. She is one of the project leaders of the Dutch Cancer Society project ‘’Cardiotoxicity and second cancer risk after treatment of aggressive B-cell Non-Hodgkin lymphoma’’ (747.568€), aiming at establishing the risk of cardiotoxicity of the R-CHOP regimen by performing both a retrospective analysis and a prospective cross-sectional case control study of R-CHOP treated patients and their siblings. This project will provide important data on the actual risk of cardiotoxicity and additional risk factors for cardiotoxicity of R-CHOP treated patients
The ESC unites national cardiac societies from around the world, including 57 countries from the EU and the Mediterranean basin. This unique network allows it to understand the impact of cardiovascular disease and to advance cardiovascular science.
The ESC’s mission is to reduce the burden of cardiovascular disease. It does this by:
Patients’ engagement: In 2018 the ESC established the Patient Forum to have professionals and patients working together in order to make a meaningful contribution to all objectives of the ESC, from the congresses and educational resources to ESC guidelines and advocacy. It brings together 25 patients from 11 countries around Europe. Each patient has personal experience with cardiovascular conditions.
This institution also has a Health Research Institute certified by regional health authorities, with a research area focused on cancer and lymphoma and a local IRB/EC. This is the first institution in Madrid and the second in Spain with a Multidisciplinary Lymphoma Unit working in the Oncohealth Institute, the comprehensive cancer center of Fundacion Jimenez Diaz University Hospital. This multidisciplinary unit has members from the Departments of Hematology (lead by Raul Cordoba, MD, PhD), Pathology, Nursing, Radiology, Nuclear Medicine, Pharmacy, Geriatrics and Dermatology.
In the Lymphoma Unit there are two multidisciplinary programs: the Geriatric Hematology Program in collaboration with Geriatrics to adapt therapy in older adults with lymphoma; and the Cardio-Oncology Program, in collaboration with the Department of Cardiology, to monitor cardiovascular toxicities in patients with cancer.
Aarhus University’s vision for 2025 will be realized through a focus on strategic commitments such as the generation of knowledge and research breakthroughs through free, independent research of the highest international quality, generation of the innovation in established public and private sector companies and startups through collaboration, both internally and with external partners and the intensification of the exchange of talents and knowledge, locally, nationally and globally.
Within its Faculty of Health, the Department of Clinical Medicine is a brickless organisation conducting both basic health science research and clinical research within all medical specialities in collaboration with Aarhus University Hospital and the regional hospitals in Central Denmark Region. Its research activities are conducted in collaboration with internationally renowned researchers in both Denmark and abroad. Key figures: 1) Approx 30,000 square meters of research facilities; 2) Approx. 2,100 publications annually; and 3) Research turnover: approx. DKK 600 million (external funding accounts for 60%). With regards to research facilities, it is pointed out:
Within the Cardiology department, there is strong interest in the role of ischemic conditioning to confer organ protection. The “Cardioprotection and myocardial metabolism”, led by Prof Botker is a translational and clinical research group within that uses small and large animal models to study the molecular basis and modulation of metabolism in cardioprotection against ischemia/reperfusion injury, and then translates into human studies. The group has led several randomized clinical trials testing the effect of RIPC in acute myocardial infarction, stroke and other acute conditions.
IPOL is the largest Portuguese cancer centre with an area of influence covering nearly four million people (southern Portugal and the Madeira and Azores islands). IPOL receives over 6,000 new cases per year, being currently responsible for the follow up of more than 57,000 patients. The Research Centre of IPOL coordinates one supportive (tumour biobank) and five functional units (basic/translational, clinical and epidemiology), devoted but not limited to two main research lines (aggressive tumours and cancer risk), as well as population-based cancer registry, epidemiology studies and clinical trials. The development of basic and applied research activities in the oncology area is based on collaborative work with national and international institutions and on advanced training of health and research professionals.
The expertise of IPOL’s research groups in genetics, cell and molecular biology, animal manipulation, and patient-centred clinical practice, supported by modernized research infrastructures and equipment, guarantees a continuous development of research projects addressing increasingly significant societal challenges. Since 2013 IPOL is a founding member of the iNOVA4Health research consortium (www.inova4health.com) together with iBET (Instituto de Biologia Experimental e Tecnológica), Centre for the Studies of Chronic Diseases (CEDOC) and ITQB (Instituto Tecnológico de Química e Biologia) both from the NOVA Medical School. The main goal of this consortium is achieving excellence in translational medicine thus amplifying IPOL’s fields of research interest and applications.
The Haematology Department at IPOL is a reference centre for the
diagnosis and treatment of haematological tumours in Portugal. Among the approximately 1,000 new patients here received per year, 50% are lymphomas. The centre has wide experience and expertise in the treatment of first line and relapsed patients, including conventional chemotherapy, immunotherapy and autologous and allogeneic hematopoietic transplantation. The team is also experienced in clinical research, participating regularly in phase 2 and phase 3 clinical trials in lymphomas. Research activities are developed with the support of the hospital’s Clinical Trial Unit. The CTU supports project development, coordination, management and statistical analysis, as well as submission and approval tasks. It is included in the hospital’s Research Centre, a structure experienced in managing collaborative projects.
An important part of the regular lymphoma patient care is the monitoring and management of late treatment toxicities including cardiovascular and second malignancies. Cardiotoxicity monitoring within the frame of this project, will be followed by the project team members at Hospital da Luz. Within the lymphoma clinical research field, the centre works in close collaboration with academic cooperative groups including the Lymphoma Study Association, LYSA (being an active member of this group), the European Haematology Association – Lymphoma Study Group (EHA LyG), the European Mantle Cell Network (EMCN) and the EORTC. The team participates in translational projects, clinical trials and observational studies. At the moment, the centre is starting a project for the validation of EORTC Quality of Life Questionnaires for Portuguese lymphoma patients’ population and in the QUALITOP project, a multidisciplinary, European cooperative project aiming at monitoring multidimensional aspects of quality of life after cancer immunotherapy, that was financed in 2019 by the Horizon 20/20 programme.
Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.
Philips Healthcare is one of the major international industries that develops medical imaging equipment. The unit involved is the Department of MR Clinical Science of Philips Medical Systems Nederland B.V. in Best, The Netherlands. The department has on-site access to multiple 1.5T and 3T MRI scanners and has large international clinical users networks in multiple clinical domains (neuro, onco, cardiovascular, musculoskeletal). The department has ample experience and expertise in MR imaging and image analysis, has been involved in multiple EU funded research projects.
At the University of Düsseldorf (DUS), a strong focus has been put on national and international collaborative projects in recent years. Various, highly renowned cardiovascular collaborative networks have been established and are active today. This includes the previous Collaborative Research Center (CRC) 612 (“Molecular analysis of myocardial function and dysfunction“; Spokesperson: Prof. Schrader), which provided major input in terms of animal models, mouse functional and metabolic imaging (e.g. with MRI), the CRC 1116 (“Master switches in cardiac ischemia“;Chairmen: Profs. Fischer, Kelm, Goedecke), which currently provides the framework for molecular infarct research addressing the interference with co- morbidities and myocardial metabolism, the IRTG 1902 (“Intra- and Interorgan communication of the cardiovascular system”; Chairmen: Profs. Gödecke and Leitinger) and the recently founded CRC “transregio” TR259 with the universities of Cologne and Bonn on aortic disease (Chairmen: Profs. Nickenig, Kelm, and Baldus).
All cardiovascular-focused departments and institutes at the campus are unified in a unique structure (the Cardiovascular Research Institute Düsseldorf, CARID, chairman: Prof. Kelm) supporting, strengthen and intensify interdisciplinary cardiovascular research in Düsseldorf. Well- networked team members of the proposed Research Initiative in Düsseldorf are involved in the above- mentioned projects (e.g. Kelm, Jung, Bönner), and provide expertise in cardiovascular research, from basic research in mice (CRC 1116 B06, B12; TR259 B03) and pigs (BO-4264/1-1) to translational research in humans with a technical focus on cardiovascular magnetic resonance (CMR).
Cardiovascular and oncologic research is a focus area at the University of Düsseldorf in basic, as well as in clinical and translational science. Professor Kelm was responsible for the German recommendations in response to the cardio-oncologic recommendations of the European society of cardiology (Der Kardiologe 2018 volume 12, pages19–25). Numerous other infrastructural initiatives have established Düsseldorf as a leading research faculty in cardiovascular medicine.
Our centre promotes the integrated patient management with screening, early diagnosis, follow up after treatment and individualized support for patients. Research is one of the fundamental missions of our centre to allow patients to benefit from diagnostic and therapeutic innovations on the basis of all the disciplines involved in the management of cancer.
Within the Henri Becquerel Anti-Cancer Center, our hematology department is a service of 50 hospital beds (including 20 beds in the hematological intensive care sector) and 18 places for ambulatory infusions. We are part of the UNICANCER network of all cancer centers in France (with more than 250 clinical trials in progress sponsored by the FCCC and 18% of the patients in the FCCC that are participating in a clinical trial), as well as member of the “LYSA” group (lymphoma study association), an internationally renowned academic group in the field of lymphoma.
We also have an INSERM research team (UMR INSERM 1245) led by Pr JARDIN, dedicated to research in the field of genetics and biomarkers of lymphoid malignancies. We participate in numerous therapeutic clinical trials of all phases, academic and industrial, in all hemopathies. Our center is INCa-associated (French National Cancer Institute) labeled for early phase clinical trials.
Organized in 11 research areas including Cardiovascular Diseases (CIBERCV), Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), Mental Health (CIBERSAM), Hepatic Diseases (CIBEREHD), Diabetes and Metabolic Diseases (CIBERDEM), Rare Diseases (CIBERER), Respiratory Diseases (CIBERES), Public Health and Epidemiology (CIBERESP), Obesity and Metabolic Diseases (CIBEROBN), Cancer (CIBERONC), Fragility and Healthy Ageing (CIBERFES), CIBER is the largest Research Network in Spain.
CIBER counts with more than 800 dedicated employees and 6,000 associated researchers integrated in more than 400 leading-edge research groups. Thanks to its network structure, CIBER is capable of bringing together more than 100 different associated institutions including Hospitals, Research Centers, Technology Centers, Private Institutions and Universities selected to join CIBER consortium on the basis of their excellence.
CIBERCV is the devoted area of CIBER cardiovascular diseases. CIBERCV has focused on achieving the following objectives: to facilitate and promote joint collaborations between basic, clinical and epidemiological researchers; to promote the shared used of advanced technological facilities; to apply research results to clinical practice and; to train a new generation of translational cardiovascular researchers in Spain. At present, CIBERCV consists of 40 research groups and research strategy is based on 4 research programs, where RESILIENCE perfectly fits:
Learning Health aims to promote the generation and dissemination of knowledge, technologies and more advanced practices in healthcare, contributing to improvements in patient safety and quality of care. HLUZ.LH is the training, research and innovation center from Luz Saúde, one of the largest private health care providers in Portugal, with 30 units (including 15 private hospitals, one hospital of the National Health Service operated under a Public-Private Partnership program, 12 private outpatient clinics and two senior residences). HLUZ.LH, as the innovation center from Luz Saúde Group, will contribute to the success of the present proposal by supporting the interactions between the different hospitals of the group and the researchers associated with this proposal to RESILIANCE. Moreover, HLUZ.LH has a team with strong background to bridge the gap between research and clinical practice. HLUZ.LH clinical trials team has coordinated over 140 clinical trials including over 400 patients.
The flagship Hospital da Luz Lisboa materializes the health care paradigm of Luz Saúde, bringing together an acute care hospital and a residential hospital in an integrated health complex.
Hospital da Luz Lisboa offers all medical and surgical services, with emphasis on differentiated areas organized in multidisciplinary centers of excellence, which contributes to a complete and integrated approach to patients and is determinant for the quality of health care provided.
LC, a worldwide network of lymphoma patient groups, was formed in 2002 and incorporated as a not for profit organisation in 2010. Its express purpose is to create a level playing field of information around the world and to facilitate a community of lymphoma patient organisations to support one another’s efforts in helping patients with lymphoma receive the care and support needed, in addition to integrate the patient perspective in research and clinical practice decision-making. Its vision focuses on equity in lymphoma outcomes across borders and its mission on enabling global impact by fostering a lymphoma ecosystem that ensures local change and evidence-based action.